FREDERICK, Md., Dec. 15, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, is calling upon cruise lines to improve decontamination and adopt hospital-grade technology like SteraMist as a compromise-free standard for advanced maritime decontamination. “The question should no longer be if cruise lines can prevent health outbreaks, but how often and how comprehensively they are utilizing hospital-grade disinfecti ...

Summary of TOMI Environmental Solutions Conference Call Company Overview - **Company Name**: TOMI Environmental Solutions - **Ticker**: TOMZ - **Industry**: Disinfection and Decontamination - **Product**: SteraMist, an eco-friendly disinfection solution developed from DARPA technology Core Points and Arguments - **Product Efficacy**: SteraMist utilizes a low-percentage hydrogen peroxide (7.8%) converted through a cold plasma arc to create hydroxyl radicals that effectively neutralize pathogens, including spores and viruses, without leaving any residue [2][3][4] - **Market Opportunity**: The global market for disinfection is vast, spanning multiple industries including biotech, food and beverages, commercial services, and healthcare, with significant growth expected [4][16] - **Competitive Landscape**: Major competitors include STERIS and Bioquell, with TOMI positioned to outperform due to its unique technology and faster, more effective disinfection capabilities [5][10] - **Client Base**: Notable clients include Pfizer, Merck, NASA, and various government agencies, which validate the product's effectiveness and reliability [3][19] - **Regulatory Compliance**: The company adheres to stringent regulations, including FDA and EMA compliance, which enhances its credibility in the market [16][20] Financial Performance - **Revenue Growth**: Revenues increased by 38% over pre-COVID levels, with a 40% growth in the first half of 2025 compared to the same period in 2024 [21][14] - **Margins**: The company maintains gross margins of approximately 60%-62% [10][23] - **Recurring Revenue Model**: The business model is based on a "razor and blade" approach, where equipment sales drive recurring revenue from consumables [10][25] Market Segments - **Biotechnology and Life Sciences**: This segment is the largest revenue generator, including applications in pharmaceuticals and clean rooms [5][6] - **Food Safety**: Growing segment with increasing demand for sanitation solutions due to stricter regulations and food safety concerns [18][19] - **Healthcare**: Significant potential for growth, especially in hospitals, where SteraMist has demonstrated effectiveness in reducing infection rates [20][21] Future Outlook - **Market Expansion**: The company is focused on expanding its sales force and enhancing training programs to penetrate more healthcare facilities and other verticals [22][23] - **Technological Advancements**: Ongoing development of custom integration units and partnerships with laboratory equipment manufacturers to embed SteraMist technology [10][11] - **Regulatory Tailwinds**: Increased focus on biosecurity and infection control post-COVID is expected to drive demand for SteraMist solutions [16][24] Additional Insights - **Case Studies**: Successful case studies, such as the reduction of C. diff cases in hospitals, provide strong evidence of product effectiveness [20] - **Environmental Impact**: SteraMist's eco-friendly profile, with water and humidity as the only byproducts, positions it favorably against traditional disinfection methods [29][30] - **Global Health Concerns**: The company is prepared to address potential outbreaks and pandemics, leveraging its technology to provide effective solutions [24] This summary encapsulates the key points discussed during the TOMI Environmental Solutions conference call, highlighting the company's strengths, market opportunities, and future growth potential.

Core Insights - TOMI Environmental Solutions, Inc. will present at the Sidoti Year End Investor Conference on December 10-11, 2025, with CEO Dr. Halden Shane and CFO David Vanston available for one-on-one meetings [1][2] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [3] - The BIT solution, developed with a defense grant from DARPA, utilizes a low percentage of hydrogen peroxide as its active ingredient and incorporates patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [3] - TOMI's products are applicable in various environments, including hospitals, biosafety labs, pharmaceutical facilities, commercial buildings, schools, and emergency services [3]

Core Viewpoint - TOMI Environmental Solutions, Inc. has filed a $50 million universal shelf registration statement with the SEC to enhance its financial flexibility for operational growth and strategic initiatives [1][2]. Financial Strategy - The registration statement will allow TOMI to offer and sell securities as needed, providing the company with the ability to efficiently access capital [2]. - TOMI has entered into a strategic advisory and placement arrangement with Bancroft Capital and established an equity line of credit (ELOC) facility with Hudson Global Ventures, allowing the sale of up to $20 million of common stock over a 24-month period [3]. Operational Performance - The CEO of TOMI highlighted strong sequential revenue growth and improved gross margins in Q3, indicating expanding customer adoption of the SteraMist® technology [4]. - The financing from the ELOC is intended to accelerate investments in innovation, manufacturing efficiency, and global distribution [4]. Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology® (BIT™) platform, which utilizes a low percentage of Hydrogen Peroxide to create a germ-killing aerosol [5]. - The company's products are designed for a wide range of commercial structures, including hospitals, cruise ships, schools, and military facilities [6].

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in iHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year-over-year in life sciences and food safety [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIT solution sales increased by 21% year-to-date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide positions the company to serve not only life sciences and healthcare but also agriculture, food processing, and environmental biosafety [7][23] - The active pipeline surpassed $15 million, encompassing both domestic and international customers across various industries [6] Company Strategy and Development Direction - The company aims to enhance customer engagement and expand its recurring revenue streams through personalized outreach and targeted marketing campaigns [8] - Focus on biosecurity advancements and scaling automation integrations for high-efficacy environments is prioritized for 2026 [8][9] - The company is investing in innovation and customer success to capture opportunities in clean tech and biosecurity [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and reaffirmed the soundness of its strategy, with steady improvement expected financially, operationally, and strategically [25][26] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26][27] Other Important Information - The company celebrated a significant addition to its customer roster with Bausch + Lomb, which adopted mobile handheld surface units and committed to BIT Solution orders for 2026 [19][20] - The company is actively pursuing the cannabis market and has opened doors to promising new partnership discussions [22] Q&A Session Summary Question: What are your sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [29] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins expected to hold steady [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while there was a decrease in solution sales growth in Q3, they expect a rebound by the end of the fourth quarter [35] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, with expectations for significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in device manufacturing for this purpose [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food processing and agriculture [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6][7] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5][8] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8][9] Management's Comments on Operating Environment and Future Outlook - Management believes the third quarter marked a decisive turning point, with a 95% sequential revenue increase driven by expanding recurring revenue streams [4][5] - The company is optimistic about the future, with a strong sales backlog and a sales strategy beginning to deliver promising results [25][26] Other Important Information - The company entered into an equity purchase agreement with Hudson Global Ventures, allowing it to sell up to $20 million in common stock over a 24-month period [26] - The SteraMist IHP technology was named the Disinfection and Decontamination Products Company of the Year 2025 [7] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management sees the food industry as a key marketing vertical and is excited about the approval, which is expected to be a game changer [29] Question: Should operating expenses and gross margins continue to improve? - Management expects operating expenses to increase but believes they will be positive in relation to revenue, with gross margins remaining stable [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has different distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: What visibility is there on solution sales in the coming quarters? - Management anticipates that solution sales will increase as more technology is deployed, with a key focus on driving growth in BIP solution sales [35] Question: Any updates on servicing military and defense markets? - The company is working with a key site looking to replace formaldehyde and expects significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical instrument sterilization? - The company is prioritizing partnerships in device manufacturing to streamline IHP into decontamination processes [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, indicating a positive trend in this segment [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food safety, agriculture, and environmental biosafety [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and strategic execution, highlighting steady improvement financially, operationally, and strategically [25] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26] Other Important Information - The company has been recognized as the Disinfection and Decontamination Products Company of the Year 2025, validating its solutions and positioning [7] - The company is expanding its training programs and customer engagement strategies to enhance market penetration [8] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [30] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins holding steady [31][32] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries focused on increasing demand for SteraMist [36] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while they had a 40% increase in solution sales earlier in the year, they expect recurring sales to rise again by the end of Q4 [37] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, expecting significant developments in 2026 [43] Question: Progress on CAR T-cell disinfection business? - No updates were provided on this front [45] Question: Expectations on the rollout by major service provider companies in healthcare mold remediation? - Management expressed optimism about rapid rollouts due to strong initial assessments and training support [46] Question: Plans to penetrate the disinfection market for data centers? - Management acknowledged the interest in data centers and the need for disinfection, indicating plans to expand the sales team for this vertical [49] Question: How is the company increasing awareness for the food industry post-FDA ruling? - The company is focusing on social media and reaching out to existing contacts in the food safety sector [51] Question: Any progress in using SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in this area [54]

Core Insights - TOMI Environmental Solutions, Inc. reported a significant sequential revenue increase of 95% in Q3 2025, driven by higher equipment purchases and strong recurring sales of its BIT™ Solution [5][10] - The company is strategically positioned for long-term growth, with ongoing investments in R&D and expanding international market penetration [10][11] Financial Performance - Revenues for Q3 2025 were $2.0 million, a 95% increase from Q2 2025, but a decrease from $2.54 million in Q3 2024 [5][25] - Gross profit margin remained stable at 61% for Q3 2025, indicating operational efficiency [5][25] - Operating loss for Q3 2025 was $(321,000), compared to an operating income of $149,000 in Q3 2024 [5][25] - Net loss for Q3 2025 was $(450,000) or $(0.02) per share, compared to a net income of $59,000 or $0.00 per share in Q3 2024 [5][25] Business Highlights - The company achieved a 21% year-over-year increase in SteraMist solution sales for the nine months ended September 30, 2025 [5] - International revenue accounted for nearly 36% of Q3 revenue, up from 20% in Q2 2025, reflecting successful global market penetration [5] - The sales order backlog grew to $0.9 million at quarter-end and expanded to $1.3 million by October 31, with approximately $3 million in pending contracts expected to close before year-end [5] Strategic Initiatives - The company is focusing on expanding its product applications across various sectors, including life sciences, healthcare, food safety, and commercial markets [5][10] - A new equity line of credit allows the company to sell up to $20 million in common stock over a 24-month period, enhancing financial flexibility [8][9] - The FDA's expanded approval for hydrogen peroxide use is expected to broaden the application of SteraMist iHP technology, targeting food, agriculture, and environmental biosecurity markets [10][12] Liquidity and Capital Access - As of September 30, 2025, the company had working capital of $2.5 million, with cash used in operations improving by approximately $876,000 compared to the same period in 2024 [7] - The company completed a $535,000 convertible note financing to support growth initiatives [7] Executive Commentary - The CEO highlighted the strong revenue growth and new customer partnerships as evidence of the effectiveness of the company's strategy and execution [10] - The company is optimistic about maintaining momentum into Q4 2025 and throughout 2026, supported by a growing customer base and expanding sales [11][12]

Core Points - TOMI Environmental Solutions, Inc. will report its third quarter results for the period ending September 30, 2025, on November 14, 2025, after market close [1] - A conference call will be held on the same day at 4:30 p.m. ET to discuss the results [1] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform [4] - BIT technology employs a low percentage of hydrogen peroxide as the active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - The company's products are applicable in various sectors, including hospitals, biosafety labs, pharmaceutical facilities, commercial buildings, schools, and emergency services [4]

Core Insights - TOMI Environmental Solutions, Inc. is actively participating in the AALAS 76th National Meeting to enhance its presence in the animal research sector [1][2] - The event serves as a platform for TOMI to strengthen strategic partnerships and promote its SteraMist Integrated System (SIS) [2][3] - The company aims to leverage high-impact networking opportunities to drive the adoption of its innovative ionized Hydrogen Peroxide (iHP) technology [3][4] Company Overview - TOMI specializes in disinfection and decontamination solutions, utilizing its Binary Ionization Technology® (BIT™) platform, which is based on low percentage hydrogen peroxide [5] - The company’s products are designed for a wide range of applications, including hospitals, biosafety labs, and food processing facilities [5] Event Participation - AALAS is a significant event for TOMI, attracting thousands of professionals from research institutions, which facilitates lead generation and collaboration [3] - The executive team, including key leaders from various departments, will represent TOMI at the event, highlighting the company's commitment to innovation and customer-centric growth [4][5]